A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation

Haematologica

Volumn 99, Issue 10, 2014, Pages 1624-1631

  Kornblit, Brian ^a   Maloney, David G ^a,b   Storer, Barry E ^a,c   Maris, Michael B ^d   Vindeløv, Lars ^e   Hari, Parameswaran ^f   Langston, Amelia A ^g   Pulsipher, Michael A ^h   Bethge, Wolfgang A ⁱ   Chauncey, Thomas R ^j   Lange, Thoralf ^k   Petersen, Finn B ^l   Hübel, Kai ^m   Woolfrey, Ann E ^a,b   Flowers, Mary E D ^a,b   Storb, Rainer ^a,b   Sandmaier, Brenda M ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Rocky Mountain Blood and Marrow Transplant Program   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g EMORY UNIVERSITY   (United States)

^h UNIVERSITY OF UTAH   (United States)

ⁱ UNIVERSITY OF TÜBINGEN   (Germany)

^j VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^k UNIVERSITY OF LEIPZIG   (Germany)

^l LDS HOSPITAL   (United States)

^m UNIVERSITY OF COLOGNE   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; TACROLIMUS; ANTINEOPLASTIC AGENT; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CYTOMEGALOVIRUS; DISEASE COURSE; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; FEMALE; GRAFT REJECTION; HAZARD RATIO; HCT COMORBIDITY INDEX; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; INCIDENCE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; MYCOSIS; MYELODYSPLASTIC SYNDROME; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE RISK SCORE; VIRUS INFECTION; VIRUS REACTIVATION; WHOLE BODY RADIATION; ADOLESCENT; ADVERSE EFFECTS; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; LEUKEMIA; LYMPHOMA; MIDDLE AGED; RECURRENT DISEASE; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; UNRELATED DONORS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RECURRENCE; SIROLIMUS; TACROLIMUS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS; YOUNG ADULT;

EID: 84907495257     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.108340     Document Type: Article

References (39)

1. Thepot S, Zhou J, Perrot A, Robin M, Xhaard A, de Latour RP, et al. The graftversus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia 2010;24(11):1852-8.
2. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R, et al. Graftversus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005;23(9):1993-2003.
3. Inamoto Y, Flowers MED, Lee SJ, Carpenter PA, Warren EH, Deeg HJ, et al. Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood 2011;118(2):456-63.
4. Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, et al. Graftversus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol 2013; 31(12):1530-8.
5. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem H-P, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997;89(8):3048-54.
6. Storb R, Raff RF, Appelbaum FR, Deeg HJ, Graham TC, Schuening FG, et al. DLAidentical bone marrow grafts after lowdose total body irradiation: the effect of canine recombinant hematopoietic growth factors. Blood 1994;84:3558-66.
7. Baron F, Sandmaier BM, Storer BE, Maris MB, Langston AA, Lange T, et al. Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versushost disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning. Biol Blood Marrow Transplant 2007;13(9):1041-8.
8. Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D, et al. HLAmatched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003;102(6):2021-30.
9. Maris MB, Sandmaier BM, Storer BE, Maloney DG, Shizuru JA, Agura E, et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant 2006; 12:454-65.
10. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000;96(6):2062-8.
11. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graftversus-host-disease prophylaxis after HLAidentical sibling bone marrow transplantation. Blood 1998;92(7):2303-14.
12. Hiraoka A, Ohashi Y, Okamoto S, Moriyama Y, Nagao T, Kodera Y, et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versushost disease prophylaxis after allogeneic bone marrow transplantation. Japanese FK506 BMT Study Group. Bone Marrow Transplant 2001;28(2):181-5.
13. Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990;144(1):251-8.
14. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. [Review]. Clin Biochem 1998;31(5):335-40.
15. Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ, et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007;109(7): 3108-14.
16. Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A, et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. [Erratum appears in Blood. 2010 May 27;115(21):4318]. Blood 2010;115(5): 1098-105.
17. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340:c332.
18. Petersdorf EW, Gooley TA, Anasetti C, Martin PJ, Smith AG, Mickelson EM, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998; 92(10): 3515-20.
19. Kahl C, Storer BE, Sandmaier BM, Mielcarek M, Maris MB, Blume KG, et al. Relapse risk among patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007; 110(7):2744-8.
20. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106(8):2912-9.
21. Al-Kadhimi Z, Gul Z, Chen W, Smith D, Abidi M, Deol A, et al. High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients. Biol Blood Marrow Transplant 2014;20(7):979-85.
22. Marty FM, Bryar J, Browne SK, Schwarzberg T, Ho VT, Bassett IV, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007; 110(2):490-500.
23. Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J, et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reducedintensity conditioning. J Clin Oncol 2008; 26(35):5767-74.
24. Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008;112(12): 4425-31.
25. Cutler C, Henry NL, Magee C, Li S, Kim HT, Alyea E, et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11(7):551-7.
26. Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003;102(5):1601-5.
27. Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ, et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004; 10(5):328-36.
28. Furlong T, Kiem H-P, Appelbaum FR, Carpenter PA, Deeg HJ, Doney K, et al. Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant 2008;14(5):531-7.
29. Cutler C, Logan BR, Nakamura R, Johnston L, Choi SW, Porter DL, et al. Tacrolimus/sirolimus vs. tacrolimus/methotrexate for graft-vs.-host disease prophylaxis after HLA-matched, related donor hematopoietic stem cell transplantation: results of Blood and Marrow Transplant Clinical Trials Network Trial 0402. Blood. 2012;120(21):Abstract 739.
30. Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, et al. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica 2012; 97(12):1882-9.
31. Pulsipher MA, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll WL, et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase III COG/PBMTC trial. Blood 2014; Feb 6 [Epub ahead of print 2014].
32. Armand P, Kim HT, Sainvil MM, Bachanova V, Devine SM, Waller EK, et al. The addition of sirolimus to the GVHD prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicenter randomized trial. Blood. 2013;122(21):Abstract 704
33. Alyea EP, Li S, Kim HT, Cutler C, Ho V, Soiffer RJ, et al. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2008;14(8):920-6.
34. Ho VT, Aldridge J, Kim HT, Cutler C, Koreth J, Armand P, et al. Comparison of tacrolimus and sirolimus (Tac/Sir) versus tacrolimus, sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versushost disease prophylaxis after reducedintensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2009;15(7):844-50.
35. Perez-Simon JA, Martino R, Parody R, Cabrero M, Lopez-Corral L, Valcarcel D, et al. The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate. Haematologica 2013; 98(4):526-32.
36. Nakamura R, Palmer JM, O'Donnell MR, Stiller T, Thomas SH, Chao J, et al. Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis. Leuk Res 2012;36(9):1152-6.
37. Khaled SK, Palmer J, Stiller T, Senitzer D, Maegawa R, Rodriguez R, et al. A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant. Bone Marrow Transplant 2013; 48(2):278-83.
38. Claxton DF, Ehmann C, Rybka W. Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based nonmyeloablative allogeneic stem cell transplantation. Br J Haematol 2005;130(2):256-64.
39. Kornblit B, Maloney DG, Storb R, Storek J, Hari P, Vucinic V, et al. Fludarabine/2 Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related HCT: A phase III randomized trial. Biol Blood Marrow Transplant 2013;19(9):1340-7.